Debbie Rigby rounds up the latest in research news
A meta-analysis and systematic review of 43 randomized trials has confirmed that inhaled long-acting bronchodilators (ILABs) are not associated with cardiovascular AEs in patients with stable COPD. LABAs might reduce the incidence of hypertension, but might increase the risk of heart failure. Therefore, COPD patients with a history of heart failure should use it with caution.
International Journal of Chronic Obstructive Pulmonary Disease 2019;14:799–808.
In this landmark CREDENCE study, the risk of kidney failure and cardiovascular events in patients with type 2 diabetes and kidney disease, was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years. There were no significant differences in rates of amputation or fracture.
New Engl J Med, published 14 April, 2019.
Dose-response curves for therapeutic, efficacy and lethality with cannabinoids have not been developed for humans. Individual dose-response is likely to be variable, depending on the symptom or surrogate marker being measured, the route of administration, individual pharmacokinetic variables and the cannabinoid being used.
British Journal of Clinical Pharmacology 2019.
A Cochrane review has concluded that memantine has a small clinical benefit of memantine in people with moderate‐to‐severe AD, which occurs irrespective of whether they are also taking a cholinesterase inhibitor, but no benefit in people with mild AD.
Cochrane Database of Systematic Reviews 2019, Issue 3.